The Economic Burden of Breast Cancer: Why Prevention Is a Sustainable Choice for the Future. Key insights from Italy.
Among the most frequently diagnosed, breast carcinoma represents both a clinical and economic challenge. Early diagnosis and screening programs can significantly reduce costs, inequalities, and the impact on quality of life.
Breast cancer generates a significant economic impact at every stage of care, with direct and indirect costs that burden healthcare systems and patients. “Financial toxicity” affects 38% of women with breast carcinoma in Italy.
Diagnosing the disease at an early stage leads to less invasive treatments, fewer hospitalizations, and lower costs. Investing in screening and prevention is a strategy for sustainable healthcare—one that reduces suffering and improves quality of life.
Breast cancer is not only one of the most significant clinical challenges in oncology, but also one of the conditions with the greatest economic impact on patients and healthcare systems. Managing breast cancer involves substantial costs throughout the entire care pathway: specialist visits, diagnostic tests, surgery, oncological treatments, rehabilitation, followup, and supportive services.
One of the most concerning issues is financial toxicity, namely the direct economic burden that patients must bear. In Italy, estimates indicate that 38% of women with breast cancer face outofpocket expenses related to managing the disease. The average annual cost is €1,665, but it can exceed €4,000 in southern regions and islands, where inequalities in access to care and a reduced availability of local services continue to persist.
These expenses include nonreimbursed medications, additional diagnostic tests, extra specialist consultations, rehabilitative treatments, as well as indirect costs such as transportation, lost workdays, and costs indirectly related to the disease—like dental care, eye examinations, and supplements.
Did you know?
Diagnosing breast cancer at an early stage is one of the most effective ways to reduce this financial burden. Earlystage tumors require less aggressive treatments, more conservative surgical procedures, and shorter therapeutic cycles. This leads to an immediate clinical benefit but also to lower costs for both healthcare systems and families.
Multiple European reports highlight prevention as a strategic pillar for sustainability: investing in screening programs, awareness, and educational initiatives not only reduces the incidence of advanced disease but also contributes to creating more resilient, equitable, and sustainable health systems. Prevention affects not only the individual—it benefits the entire community.
Investing in women’s health means reducing direct and indirect costs, improving quality of life, and decreasing territorial and socioeconomic disparities. A strong preventive approach allows valuable resources to be reinvested into innovation, research, and new therapeutic pathways.
Prevention is, therefore, a clinical, social, and economic act.
A simple action—such as participating in a screening program—can generate a concrete and lasting benefit for the individual, the family, and the entire healthcare system.
Sources: ANSA, Pharmastar March 2025